XGBoost improves retrospective vancomycin concentration prediction
Source check: Source checked. Not independent scientific confirmation.
Finding: XGBoost selected or averaged pharmacokinetic models using routine patient characteristics in 343,636 adult vancomycin records from 156 centres. A separate test set showed better concentration prediction than individual models and simple averaging, although some gains were modest. This retrospective evaluation did not test resulting dose decisions, toxicity, treatment success or benefit to patients.
Technology: XGBoost; binary-relevance multilabel classification
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Six XGBoost classifiers estimate which pharmacokinetic models will predict concentrations acceptably, enabling patient-specific ranking or weighted averaging.
- Test and result
- Distinct-patient 70:15:15 development/validation/test split, with measured drug concentrations as the reference.
- Limitation / still unknown
- Prospective dose decisions, toxicity reduction and clinical benefit remain untested; routinely recorded covariates explain only part of model-performance variation.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12521055/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary relevant model Methods, Results and limitations; exact primary identity and current primary PubMed correction/retraction relationships checked..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.